Zobrazeno 1 - 10
of 101
pro vyhledávání: '"Thomas R Moench"'
Autor:
Emilie Mausser, Ellena Nador, Joseph A Politch, Michael R Pauly, Jai G Marathe, Thomas R Moench, Larry Zeitlin, Kevin J Whaley, Deborah J Anderson
Publikováno v:
PLoS ONE, Vol 18, Iss 3, p e0282147 (2023)
High rates of unintended pregnancies worldwide indicate a need for more accessible and acceptable methods of contraception. We have developed a monoclonal antibody, the Human Contraception Antibody (HCA), for use by women in vaginal films and rings f
Externí odkaz:
https://doaj.org/article/be5acf215cfe4c2b96bdb4513195bae6
Autor:
Joseph A Politch, Susan Cu-Uvin, Thomas R Moench, Karen T Tashima, Jai G Marathe, Kate M Guthrie, Howard Cabral, Tara Nyhuis, Miles Brennan, Larry Zeitlin, Hans M L Spiegel, Kenneth H Mayer, Kevin J Whaley, Deborah J Anderson
Publikováno v:
PLoS Medicine, Vol 18, Iss 2, p e1003495 (2021)
BackgroundMB66 film is a multipurpose prevention technology (MPT) product with monoclonal antibodies (mAbs) against HIV-1 (VRC01-N) and HSV-1 and 2 (HSV8-N). The mAbs were produced by transient expression in Nicotiana benthamiana (N). We conducted a
Externí odkaz:
https://doaj.org/article/080a0cd6780b4946ae5836420c4ae97a
Autor:
Thuy Hoang, Emily Toler, Kevin DeLong, Nomfuneko A Mafunda, Seth M Bloom, Hannah C Zierden, Thomas R Moench, Jenell S Coleman, Justin Hanes, Douglas S Kwon, Samuel K Lai, Richard A Cone, Laura M Ensign
Publikováno v:
PLoS Pathogens, Vol 16, Iss 1, p e1008236 (2020)
Bacterial vaginosis (BV), a condition in which the vaginal microbiota consists of community of obligate and facultative anaerobes rather than dominated by a single species of Lactobacillus, affects ~30% of women in the US. Women with BV are at 60% in
Externí odkaz:
https://doaj.org/article/ec5ae9c7663a4314ad6929bbc4c39a75
Autor:
Randy M Stalter, Thomas R Moench, Kathleen M MacQueen, Elizabeth E Tolley, Derek H Owen, for the Consortium for Ring Adherence
Publikováno v:
Journal of the International AIDS Society, Vol 19, Iss 1, Pp n/a-n/a (2016)
Introduction Poor adherence to product use has been observed in recent trials of antiretroviral (ARV)‐based oral and vaginal gel HIV prevention products, resulting in an inability to determine product efficacy. The delivery of microbicides through
Externí odkaz:
https://doaj.org/article/a9c1ca96e9de44e7b8cb6e083d7e9f96
Publikováno v:
PLoS ONE, Vol 8, Iss 11, p e80074 (2013)
Lactic acid at sufficiently acidic pH is a potent microbicide, and lactic acid produced by vaginal lactobacilli may help protect against reproductive tract infections. However, previous observations likely underestimated healthy vaginal acidity and t
Externí odkaz:
https://doaj.org/article/cbc296ac7c154489bb9b97b95935f99d
Autor:
Clare F Price, David Tyssen, Secondo Sonza, Ashley Davie, Sonya Evans, Gareth R Lewis, Shirley Xia, Tim Spelman, Peter Hodsman, Thomas R Moench, Andrew Humberstone, Jeremy R A Paull, Gilda Tachedjian
Publikováno v:
PLoS ONE, Vol 6, Iss 9, p e24095 (2011)
UnlabelledSPL7013 Gel (VivaGel(®)) is a microbicide in development for prevention of HIV and HSV. This clinical study assessed retention and duration of antiviral activity following vaginal administration of 3% SPL7013 Gel in healthy women. Particip
Externí odkaz:
https://doaj.org/article/bdfe8b68946e44cf931a6d338a6ecc77
Autor:
Elizabeth T Montgomery, Cynthia Woodsong, Petina Musara, Helen Cheng, Tsungai Chipato, Thomas R Moench, Freya Spielberg, Ariane van derStraten
Publikováno v:
Journal of the International AIDS Society, Vol 13, Iss 1, Pp 30-30 (2010)
Background Adherence problems with coitally dependent, female‐initiated HIV prevention methods have contributed to several trials' failure to establish efficacy. Continuous use of a cervical barrier with once‐daily cleaning and immediate reinsert
Externí odkaz:
https://doaj.org/article/4f061492f69847d393274b670bf7180a
Publikováno v:
BMC Microbiology, Vol 19, Iss 1, Pp 1-8 (2019)
Abstract Background Lactic acid (protonated lactate) has broad antimicrobial activity. Vaginal lactobacilli produce lactic acid, and are known to confer protection against reproductive tract infections when they are predominant in the vaginal microbi
Externí odkaz:
https://doaj.org/article/6ba72b301f07437da52fd8847e769d05
Autor:
Andrea R. Thurman, Thomas R. Moench, Marshall Hoke, Joseph A. Politch, Howard Cabral, Emilie Mausser, Ellena Nador, Josh Morton, Krystal Hamorsky, Kelsi Swope, Barry Bratcher, Deborah J. Anderson, Kevin J. Whaley
Publikováno v:
American Journal of Obstetrics and Gynecology.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6a90972b82b758e750b545bf6beec626
https://doi.org/10.1016/j.ajog.2023.02.024
https://doi.org/10.1016/j.ajog.2023.02.024
Autor:
Thomas R. Moench, Lakshmi Botta, Brian Farrer, Jason D. Lickliter, Hyunah Kang, Yoona Park, Cheolmin Kim, Marshall Hoke, Miles Brennan, Morgan D. McSweeney, Zachary Richardson, John B. Whelan, Jong Moon Cho, Soo Young Lee, Frances Faurot, Jeff Hutchins, Samuel K. Lai
RationaleAlthough COVID-19 is predominantly a respiratory tract infection, current antibody treatments are administered by systemic dosing. We hypothesize that inhaled delivery of a muco-trapping monoclonal antibody would provide a more effective and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2f50381f720d81c82120571a038475f2
https://doi.org/10.1101/2022.08.17.22278748
https://doi.org/10.1101/2022.08.17.22278748
